Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$682.8MCash on Hand
48.5mo Cash Runway
Follow IRON by emailGet an email when IRON reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IRON, unsubscribe in one click. Privacy
📣 What IRON Says Is Next
in 2027 · Selcodebart: “Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027 DISC-3405: Anti-TMPRSS6 Antibody (Hepcidin Induction)”
Company press release, Nov 5, 2026 · SEC filing
by the end of 2026 · Selcodebart: “Based on these results, Disc plans to resubmit a New Drug Application (NDA) to the U.S. FDA by the end of 2026, with a decision from the agency anticipated by mid-2027 Selcodebart (DISC-0974): Anti-Hemojuvelin Antibody (Hepcidin Suppression)”
Company press release, Nov 5, 2026 · SEC filing
mid-2027 · Bitopertin: “Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for potential approval in EPP anticipated by mid-2027”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Clinical trial Disc Medicine reported a positive Phase 3 APOLLO trial of bitopertin in EPP, meeting both co-primary endpoints, and plans an NDA resubmission by year-end 2026. Q3 cash was $682.8 million, with about $485.9 million in net offering proceeds in October. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing Disc Medicine filed a prospectus supplement for an at-the-market offering of up to $189,925,765 of common stock through TD Cowen as sales agent. The stock closed at $83.28 on November 4, 2026, and TD Cowen's commission is up to 3.0% of gross proceeds. Form 424B5 · SEC filing
Oct 22, 2026 ·
Financing Priced an underwritten offering of 6,000,000 common shares at $75.00 per share, with a 30-day option for up to 900,000 more. Net proceeds are expected to be about $422.4 million, or $485.9 million if the option is exercised in full. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
Financing Disc Medicine is offering 6,000,000 shares of common stock at $75.00 per share, for gross proceeds of $450,000,000. Underwriters have a 30-day option to buy up to 900,000 more shares. Closing is expected on or about October 22, 2026. Form 424B5 · SEC filing
Oct 20, 2026 ·
Financing Disc Medicine proposes a $350 million offering of common stock and pre-funded warrants, with an underwriter option for an additional $52.5 million. The stock closed at $78.93 on October 19, 2026. Offering price and underwriting terms are still blank in this preliminary prospectus. Form 424B5 · SEC filing
Oct 19, 2026 ·
Clinical trial Disc Medicine reported positive topline results from the Phase 3 APOLLO trial of bitopertin in EPP, meeting all primary and secondary endpoints. PPIX fell 41.4% vs. placebo (p<0.0001) and time in light without pain rose 12.2 hours vs. placebo (p=0.0010). The company plans an NDA resubmission by end of 2026. Form 8-K · SEC filing · Press release
Sep 10, 2026 ·
Clinical trial Disc Medicine reported initial RESTORE-PV Phase 2 results for DISC-3405 in polycythemia vera. In 13 patients completing 26 weeks, mean phlebotomy events fell from 4.0 to 0.6 (p<0.0001), and 61.5% remained phlebotomy-free. Mean hematocrit stayed below 45%. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1/2 · Recruiting · Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia Registry primary completion date, not a results date
Jun 2027 · Phase 1 · Recruiting · A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) Registry primary completion date, not a results date
Jul 2027 · Phase 2 · Active Trial · A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) Registry primary completion date, not a results date
Jun 2028 · Phase 2/3 · Enrolling · HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP Registry primary completion date, not a results date
Oct 2026 · Phase 2 · Recruiting · Study of DISC-0974-201 in Participants With IBD and Anemia Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IRON holds $682.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $42.2M/quarter from operations,
an estimated runway of 48.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:7 · Low
Cash runway 48 months
ATM program on file since Nov 2026 +15
Shelf registration (S-3ASR, Aug 2024) +10
Company says cash lasts into 2030 -15We believe that our cash, cash equivalents and marketable securities, including the net proceeds of our October 2026 underwritten public offering, will be sufficient to fund our current operating and capital expenditure plans and our debt service obligations into 2030, without taking into account any potential net…10-Q, Nov 2026
Share count +21% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Share count 45,540,842 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IRON picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRON and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.